Why women's health is becoming infrastructure

Executive Summary Women's health is transitioning from a consumer discretionary category to essential healthcare infrastructure—a shift driven by three structural forces: (1) the recognition that women's health transitions (puberty, fertility, perimenopause, menopause) are critical intervention windows for lifelong disease prevention, (2) the integration of women's health into employer benefits and payer value-based care models, and (3) the emergence of longitudinal data platforms that enable continuous, personalized care across the female lifespan. This infrastructure shift mirrors historical precedents in oncology, cardiology, and diabetes care—where specialized, transition-focused care became standard of care and drove both clinical outcomes and economic value. The infrastructure thesis has three components: (1) clinical infrastructure (specialized providers, integrated care teams), (2) data infrastructure (longitudinal biomarkers, AI-driven insights), and (3) financial infrastructure (insurance coverage, employer benefits, value-based contracts). Companies that build across all three layers will capture disproportionate value.

Part 1: The Clinical Infrastructure Shift From Episodic to Longitudinal Care Historically, women's health has been episodic and fragmented:
- Adolescent girls see pediatricians for puberty questions
- Reproductive-age women see OB/GYNs for contraception and pregnancy
- Midlife women see primary care for menopause symptoms
- Older women see cardiologists for cardiovascular disease Each encounter is disconnected from the previous one. A woman's PCOS diagnosis at age 25 is not integrated with her perimenopause care at age 45. Her cardiovascular risk factors identified at age 50 are not connected to her metabolic history from age 30. Transition-specific platforms are reversing this fragmentation by building longitudinal care models that follow women across decades: Allara Health integrates PCOS, endometriosis, obesity, and hypothyroidism into a single longitudinal care plan, recognizing that these conditions share metabolic and hormonal roots Maven Clinic spans fertility → pregnancy → postpartum → menopause, enabling providers to see the full reproductive arc Elektra Health's HelloMeno ACA health plan (launched Jan 2026 with Oscar Health in 11 states) integrates menopause care into a broader health plan, enabling coordination with primary care and cardiology across the lifespan This longitudinal approach enables predictive medicine: providers can identify women at high risk for cardiovascular disease during perimenopause because they have metabolic data from PCOS management in their 30s. They can anticipate bone loss during menopause because they have calcium metabolism data from pregnancy and postpartum. The Multidisciplinary Care Model Traditional women's health has been siloed by specialty:
- Fertility specialists manage ovulation
- Dermatologists manage hirsutism
- Cardiologists manage cardiovascular risk
- Psychiatrists manage mood disorders Transition-specific platforms are building multidisciplinary teams that address the root causes of women's health conditions: Allara Health's model (OB/GYN + endocrinologist + dietitian):
- Addresses PCOS as a metabolic disease, not just a fertility problem
- Integrates endocrinology expertise to manage insulin resistance
- Adds nutrition science to address dietary drivers of hyperandrogenism
- Result: 5% BMI reduction, 9% HbA1c reduction, 12% HOMA-IR reduction in 9 months Gennev's model (virtual menopause care + sexual health + OB/GYN specialization):
- Addresses menopause as a comprehensive health transition, not just symptom management
- Integrates sexual health expertise (often overlooked in menopause care)
- Aetna-covered nationwide, enabling scale
- One of the earliest dedicated menopause telehealth platforms (founded 2016) Elektra Health's model (virtual care + ACA health plan integration):
- Integrates menopause care into a broader health plan, enabling coordination with primary care and cardiology
- Addresses menopause as a preventive care opportunity, not a reactive symptom-management problem
- HelloMeno ACA plan (Jan 2026) demonstrates innovative health plan integration This multidisciplinary approach is clinically superior because it addresses root causes rather than symptoms. It's also economically superior because it reduces downstream complications and emergency care utilization. The Specialization Advantage As women's health transitions become recognized as critical intervention windows, specialization is becoming a competitive advantage: Spruce Biosciences is developing the first non-steroidal therapy for CAH in 50+ years, targeting a rare but serious condition that requires deep endocrinology expertise Allara Health is hiring Dr. Heather Huddleston (UCSF reproductive endocrinologist and PCOS researcher) as CMO to deepen clinical expertise Evernow is building a specialized menopause telehealth platform with celebrity backing (Gwyneth Paltrow, Drew Barrymore, Cameron Diaz) and partnerships (Clearblue, Talkspace) Evvy is building a vaginal microbiome discovery platform with 75,000+ patients and 2,000 healthcare providers, creating a specialized data asset Specialization creates clinical moats: a generalist telehealth platform cannot compete with Allara Health on PCOS outcomes because it lacks the endocrinology expertise. A generalist menopause platform cannot compete with Gennev because it lacks the longitudinal sexual health and menopause-specific data.

Part 2: The Data Infrastructure Shift From Episodic Testing to Continuous Biomarker Monitoring Historically, women's health diagnostics have been episodic:
- A woman gets her thyroid checked once every 2-3 years
- She gets her lipids checked at an annual physical
- She gets her hormones checked once during fertility evaluation Transition-specific platforms are building continuous biomarker monitoring that enables early detection and intervention: Hormona's model (at-home hormone testing + AI):
- Monthly urine hormone testing (estrogen, progesterone, FSH)
- AI pattern analysis to identify cycle irregularities and hormonal imbalances
- 2M+ data points across 185+ countries
- 90%+ accuracy vs venous blood testing
- Seed funding: $6.7M (May 2025) Evvy's model (vaginal microbiome + clinical integration):
- At-home metagenomic sequencing of vaginal microbiome
- 75,000+ patients; 2,000 healthcare providers using platform
- Launched at-home clinical care program (Dec 2025) to integrate diagnostics with treatment
- Series A: $19M
- Enables early detection of BV, yeast infections, and other vaginal health issues Hertility's model (10-hormone panel + cycle-specific recommendations):
- Comprehensive hormone testing (not just 4 hormones like competitors)
- Cycle-specific recommendations for reproductive-age women
- Series A: $16.3M (May 2025)
- Enables comprehensive hormonal assessment AOA Dx's model (multi-omic blood test for ovarian cancer):
- Blood test using tumor-associated gangliosides + AI
- 94.8% sensitivity in early-stage ovarian cancer
- Addresses a major diagnostic gap where traditional screening (CA-125, ultrasound) has poor sensitivity
- Demonstrates how transition-specific diagnostics can enable early detection This continuous monitoring approach is clinically superior because it enables early detection and intervention before symptoms develop. It's also economically superior because early intervention is cheaper than treating advanced disease. The AI-Driven Interpretation Layer Raw biomarker data is only valuable if it's interpreted correctly and acted upon. Transition-specific platforms are building AI-driven interpretation layers that turn data into actionable insights: Allora Health's clinical approach:
- Multidisciplinary team reviews biomarker data in context of patient history
- Personalized care plans based on metabolic and hormonal profile
- Continuous protocol refinement based on outcomes data Hormona's AI:
- Pattern analysis to identify cycle irregularities
- Personalized insights based on 2M+ data points
- Enables early detection of hormonal imbalances Celmatix's approach (biomarker-driven drug discovery):
- Uses large female reproductive health dataset to identify biomarkers
- Enables precision therapeutics for PCOS, endometriosis, ovarian aging
- Demonstrates how transition-specific data can drive drug discovery Evernow's platform:
- Personalized clinician matching based on patient needs
- AI-supported care coordination
- Medication delivery integrated with digital platform This AI-driven interpretation is clinically superior because it enables personalized medicine at scale. A clinician cannot manually analyze 2M+ hormone data points; AI can. It's also economically superior because it enables automation and scale. The Data Moat Companies that build longitudinal, multi-modal biomarker datasets create defensible competitive advantages: Allara Health: 1,500+ patients with longitudinal PCOS and metabolic data Evvy: 75,000+ patients with vaginal microbiome data Hormona: 2M+ hormone data points across 185+ countries Gennev: Longitudinal menopause and sexual health data from early-mover position Celmatix: Decades-long female reproductive health dataset These datasets enable:
1. Continuous protocol refinement: as more data accumulates, care protocols improve
2. Proprietary insights: competitors cannot replicate the insights without the data
3. Research partnerships: pharma companies pay for access to these datasets
4. Regulatory advantages: large datasets support FDA submissions and payer negotiations

“The AI-Driven Interpretation Layer Raw biomarker data is only valuable if it's interpreted correctly and acted upon.”

Part 3: The Financial Infrastructure Shift Insurance Coverage as the Critical Inflection Point Historically, women's health has been cash-pay or out-of-pocket:
- Fertility treatments are often not covered by insurance
- Menopause care is often not covered by insurance
- PCOS management is often not covered by insurance Transition-specific platforms are securing insurance coverage, which is the critical inflection point for scale: Insurance-Covered Menopause Platforms:
- Gennev: Aetna-covered nationwide (first-mover advantage)
- Allara Health: All 50 states (Aetna, BCBS, Cigna, Humana, UnitedHealthcare)
- Elektra Health: 11 states (Oscar Health ACA plan, Jan 2026) Insurance-Covered Fertility Platforms:
- Progyny: 600+ employers, 120+ countries (public company)
- Carrot Fertility: Thousands of employers globally
- Kindbody: Hundreds of employers (vertical integration enables better economics) Insurance coverage dramatically improves unit economics:
- Patient acquisition cost drops: insurance-covered care is easier to market (lower out-of-pocket costs)
- Lifetime value increases: insurance reimbursement is higher than cash-pay pricing
- Churn decreases: patients are more likely to stay in insurance-covered programs
- Payer data access: insurers provide claims data that enables outcomes measurement Allara Health's growth trajectory illustrates this dynamic:
- Series A (~$10M): Launched with insurance partnerships
- Series B ($26M, Jan 2025): 4x revenue growth in 2024 following insurance expansion
- Total funding: $38.5M The acceleration was driven by insurance coverage expansion and payer adoption. Employer Benefits as a Distribution Channel Employers are increasingly adopting transition-specific benefits because they directly impact workforce productivity and retention: Menopause Benefits Adoption:
- 4% of employers (2023) → 15% (2024) → projected 25%+ (2026)
- Employers recognize that menopause symptoms (hot flashes, insomnia, brain fog) directly impact productivity
- Menopause benefits are positioned as a retention tool for high-value midlife female employees Fertility Benefits Adoption:
- 30% of employers (2020) → 42% (2024)
- 450+ Fortune 500 companies offer fertility benefits
- 60,000 employees used employer-sponsored egg freezing in 2024
- Fertility benefits are positioned as a talent acquisition tool for reproductive-age women Employer Benefit Platforms:
- Progyny: 600+ employers (public company, NASDAQ: PGNY)
- Carrot Fertility: Thousands of employers
- Maven Clinic: Thousands of employers and health plans
- Kindbody: Hundreds of employers (vertical integration)
- Valerie (perimenopause supplements): Targeting employer benefits channel (£514K pre-seed, May 2025)
- Evela Health (menopause workplace benefits): B2B employer platform
- Peppy (menopause + fertility + MSK): Enterprise focus Employer adoption is accelerating because:
1. Regulatory tailwind: proposed federal rule creates "excepted benefits" category for fertility, lowering barriers for small employers
2. Competitive pressure: tech and financial services companies are using fertility and menopause benefits as recruiting tools
3. Outcomes data: platforms like Allara Health and Gennev are publishing outcomes that justify employer investment Value-Based Contracting As transition-specific platforms accumulate longitudinal outcome data, they're moving from visit-based reimbursement to value-based contracting: Allara Health's value proposition to payers:
- $3,000+ per patient annual cost savings
- 5% BMI reduction, 9% HbA1c reduction, 12% HOMA-IR reduction
- 69% of patients with irregular cycles report improved menstrual regularity
- 78% report diet improvements; 56% report exercise improvements Gennev's value proposition to payers:
- Aetna-covered nationwide demonstrates payer confidence
- Early-mover advantage in menopause care enables outcomes data
- Sexual health integration addresses often-overlooked menopause symptom Elektra Health's innovative model:
- ACA health plan integration (HelloMeno with Oscar Health, Jan 2026)
- Demonstrates novel approach to value-based menopause care
- Enables coordination with primary care and cardiology These outcomes enable risk-sharing contracts where payers pay based on outcomes (e.g., cost reduction, screening adherence) rather than visit volume. This is economically superior for both payers and platforms:
- Payers: align incentives with outcomes
- Platforms: higher margins if outcomes are achieved